OBJECTIVE To observe and evaluate the value of utilizing selective internal iliac artery infusion and selective internal iliac artery embolization for the treatment of unremitting gross hematuria of stage T4 bladder c...OBJECTIVE To observe and evaluate the value of utilizing selective internal iliac artery infusion and selective internal iliac artery embolization for the treatment of unremitting gross hematuria of stage T4 bladder carcinoma. METHODS Fifty-eight stage T4 bladder carcinoma patients were selected. The patients were grouped to the TAI group and the TAE group. The main symptom of hemorrhage was gross hematuria. None of the patients in our study could receive trunk embolization. The infusion plan was oxaliplatin （100 mg/m2） and epirubicin （EPI 50mg/m2）. Embolization was done with coils or strips of gelatin sponge. The duration of gross hematuria was observed. Routine urinalysis and routine blood examination were performed. EORTC QLQ-C30 was used to evaluate the quality of life before and after treatment. RESULTS Gross hematuria and hematuria by light microscope in all patients were reviewed. Resolution time of gross hematuria in the TAI group was 6.7 ± 1.8 days and that in the TAE group was 3.5 ± 0.7 days. The changes in routine urianlysis, routine blood examination and EORTC QLQ-C30 are shown in Figs.l-3. Gross hematuria disappeared in both groups within 7 days after treatment, but the time for the gross hematuria to resolve in the TAE group was much less than that in TAI group （t = 2.51, P 〈 0.01）, and there were no significant differences in the 7th and 21st day between the 2 groups. On the 90th day, the number of erythrocytes in the urine was near 30, close to gross hematuria. The EORTC QLQ-C30 scores decreased after interventional therapy in both groups, which means that quality of life was increased, but there were no significant differences between the 2 groups. CONCLUSION Selective internal iliac artery infusion and selective internal iliac artery embolization are safe, and, in our study, therapeutic efficacy was satisfactory in treating unremitting gross hematuria of stage T4 bladder carcinoma in patients who could not receive trunk embolization. TAE can stop gross hematuria in the short term, but it can be used just once and the long-term therapeutic effect is not satisfactory. TAI had a therapeutic effect similar to TAE, but for a shorter duration, and TAI can be performed multiple times. TAI is one of the facultative treatments for treating gross hematuria of stage T4 bladder carcinoma.展开更多
Lithium(Li)dendrite formation/evolution with its disastrous safety issues has been challenging in high-energy Li-metal batteries.The detrimental Li dendrite is primarily initiated by an inhomogeneous distribution of c...Lithium(Li)dendrite formation/evolution with its disastrous safety issues has been challenging in high-energy Li-metal batteries.The detrimental Li dendrite is primarily initiated by an inhomogeneous distribution of current density that results in uncontrollable Li deposition in the vertical direction.To suppress the Li dendrite formation through selective Li infusion and uniform Li deposition,a unique Janus-structured surface consisting of Zn@Li layer and Ag layers was fabricated on carbon cloth(CC)by step-wise magnetron sputtering.The lower-half Zn layer,enabling selective Li infusion and the rational formation of a Zn@Li layer,was able to regulate the loading amounts of Li metal.Simultaneously,the upper-half lithiophilic Ag layer and derived AgLi layer prevented the vertical Li growth due to a uniform Li deposition.Importantly,the bifunctional surface design guaranteed a sustainable exposure of lithiophilic sites upon Li nucleation/evolution.Interestingly,the symmetrical cells and full cells utilizing the Janus-structured CC@Zn@Li/Ag anode exhibited superior cycling stability and rate capability.We believe that this novel design on the Janus-structured Li anode can advance the development of safe and durable Limetal batteries.展开更多
文摘OBJECTIVE To observe and evaluate the value of utilizing selective internal iliac artery infusion and selective internal iliac artery embolization for the treatment of unremitting gross hematuria of stage T4 bladder carcinoma. METHODS Fifty-eight stage T4 bladder carcinoma patients were selected. The patients were grouped to the TAI group and the TAE group. The main symptom of hemorrhage was gross hematuria. None of the patients in our study could receive trunk embolization. The infusion plan was oxaliplatin （100 mg/m2） and epirubicin （EPI 50mg/m2）. Embolization was done with coils or strips of gelatin sponge. The duration of gross hematuria was observed. Routine urinalysis and routine blood examination were performed. EORTC QLQ-C30 was used to evaluate the quality of life before and after treatment. RESULTS Gross hematuria and hematuria by light microscope in all patients were reviewed. Resolution time of gross hematuria in the TAI group was 6.7 ± 1.8 days and that in the TAE group was 3.5 ± 0.7 days. The changes in routine urianlysis, routine blood examination and EORTC QLQ-C30 are shown in Figs.l-3. Gross hematuria disappeared in both groups within 7 days after treatment, but the time for the gross hematuria to resolve in the TAE group was much less than that in TAI group （t = 2.51, P 〈 0.01）, and there were no significant differences in the 7th and 21st day between the 2 groups. On the 90th day, the number of erythrocytes in the urine was near 30, close to gross hematuria. The EORTC QLQ-C30 scores decreased after interventional therapy in both groups, which means that quality of life was increased, but there were no significant differences between the 2 groups. CONCLUSION Selective internal iliac artery infusion and selective internal iliac artery embolization are safe, and, in our study, therapeutic efficacy was satisfactory in treating unremitting gross hematuria of stage T4 bladder carcinoma in patients who could not receive trunk embolization. TAE can stop gross hematuria in the short term, but it can be used just once and the long-term therapeutic effect is not satisfactory. TAI had a therapeutic effect similar to TAE, but for a shorter duration, and TAI can be performed multiple times. TAI is one of the facultative treatments for treating gross hematuria of stage T4 bladder carcinoma.
基金supported financially by the National Key Research and Development Program of China(grant no.2021YFB2400202)the National Natural Science Foundation of China(grant no.52104313)+1 种基金the Key Research and Development Plan of Shaanxi(grant no.2024GH-YBXM-11)the Foshan Science and Technology Innovation Team Project(grant no.1920001004098).
文摘Lithium(Li)dendrite formation/evolution with its disastrous safety issues has been challenging in high-energy Li-metal batteries.The detrimental Li dendrite is primarily initiated by an inhomogeneous distribution of current density that results in uncontrollable Li deposition in the vertical direction.To suppress the Li dendrite formation through selective Li infusion and uniform Li deposition,a unique Janus-structured surface consisting of Zn@Li layer and Ag layers was fabricated on carbon cloth(CC)by step-wise magnetron sputtering.The lower-half Zn layer,enabling selective Li infusion and the rational formation of a Zn@Li layer,was able to regulate the loading amounts of Li metal.Simultaneously,the upper-half lithiophilic Ag layer and derived AgLi layer prevented the vertical Li growth due to a uniform Li deposition.Importantly,the bifunctional surface design guaranteed a sustainable exposure of lithiophilic sites upon Li nucleation/evolution.Interestingly,the symmetrical cells and full cells utilizing the Janus-structured CC@Zn@Li/Ag anode exhibited superior cycling stability and rate capability.We believe that this novel design on the Janus-structured Li anode can advance the development of safe and durable Limetal batteries.
